Prognostic Impact of NPM1 and FLT3 Mutations in Patients With AML in First Remission Receiving Oral Azacitidine Maintenance
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
Blood 2022 Aug 12;[EPub Ahead of Print], H Döhner, AH Wei, GJ Roboz, P Montesinos, FR Thol, F Ravandi, H Dombret, K Porkka, I Sandhu, BS Skikne, WL See, M Ugidos, A Risueño, ET Chan, A Thakurta, CL Beach, D Lopes de MenezesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.